Skip to main content

Table 1 Summary of patient demographics, co-morbidities and treatment regimes

From: The relationship between clinical phenotype and kallikrein-kinin bioregulation in different forms of arthritis

 

Study Group

Group Comparisonsa

OA

Gout

RA

OA vs. Gout

OA vs. RA

Gout vs. RA

Patient Demographics

  

 Number of Patients (n)

29

10

8

-

-

-

 Sex (M/F)

5/24

7/3

4/4

0.002

0.056

0.387

 Age (years)

69 (61–73)

67 (40–78)

77 (68–78)

0.437

0.317

0.637

 BMI (kg/m2)

27 (25–36)

28 (25–32)

28 (22–30)

0.417

0.341

1

 Disease Duration (years)

5 (2.5–10)

8 (6–13)

10 (5–14)

1

0.274

1

 Smoker (Past/Current)

6/2

2/1

2/1

0.662

0.873

0.924

 Standard Drinks (n per week)

0 (0–2)

9 (5–40)

1 (0–4)

0.017

0.535

0.029

Co-morbidities

 Hypertension

12

6

3

0.567

0.074

0.057

 Diabetes Mellitus

6

0

0

0.059

0.046

-

 Hypothyroidism

4

0

0

0.131

0.108

-

 Renal Impairment

3

1

2

0.795

0.722

0.605

 Other Condition/s

11

3

2

0.409

0.144

0.577

Treatment Regimes

 Analgesics

8

6

2

0.065

0.844

0.138

 Anti-arrhymthmics

0

0

1

-

0.054

0.25

 Antibiotics

2

1

0

0.751

0.445

0.357

 Anti-depressants

5

1

0

0.66

0.207

0.331

 Anti-hypertensives

8

5

3

0.195

0.587

0.596

 Anti-inflammatory agents

6

5

0

0.076

0.16

0.019

 Antiplatelets, Anticoagulants

4

5

3

0.01

0.13

0.457

 Benzodiazepine

2

1

1

0.751

0.607

0.867

 Beta-blockers

2

4

0

0.012

0.445

0.043

 Anti-resorptives, Calcium, Vit D

3

2

1

0.431

0.862

0.671

 Corticosteroids

0

3

4

0.002

 < 0.001

0.387

 Diuretics

2

2

0

0.239

0.445

0.18

 DMARDs

1

0

5

0.552

 < 0.001

0.003

 Lipid Lowering Therapy

4

5

2

0.019

0.446

0.28

 NSAIDs

6

4

2

0.228

0.793

0.502

 Proton Pump Inhibitors

5

5

2

0.041

0.62

0.28

 Xanthine Oxidase Inhibitors

0

6

0

 < 0.001

-

0.007

  1. Data was presented as number of subjects or median (interquartile range)
  2. a P-values were calculated using the Mann-Whitney U test